Patent · US Active

Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-Ile347 polymorphism

US8420321B2 · kind B2 · utility

0Cited by

3References

3Claims

0Family size

Assignee

Sanofi-Aventis Deutschland GMBH · DE

Inventors

Detlef Kozian · Kelkheim, DE
Stefan Schaefer · Wetzlar, DE
Bernward Schoelkens · Kelkheim, DE
Karl-Ernst Siegler · Ludwigshafen, DE
Jean-Francois Deleuze · Paris, FR
Sylvain Ricard · Paris, FR
Sandrine Mace · Jouy-en-Josas, FR

Key dates

Filing date	May 17, 2011
Grant date	Apr 16, 2013
Priority date	—
Expiry date	May 17, 2031

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S436/811
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.